United States-based BioStem Technologies Inc, a global life sciences corporation, has chosen United States-based ProcessPro's Global ERP solution to streamline and optimise its biopharmaceutical manufacturing, API repackaging and pharmaceutical reformulation operations, it was reported yesterday.
BioStem Technologies says that its decision to collaborate with ProcessPro was driven by a desire to consolidate business processes into one centralised, real-time ERP solution. ProcessPro Global intends to assist with the certification and compliance needs of FDA regulations with full forward and backward lot traceability and robust reporting.
Joe Blauert, ProcessPro general manager, said, 'BioStem Technologies has solidified their commitment to growth and success with their choice of ProcessPro Global. The pharmaceutical industry is highly regulated, and BioStem Technologies will stay competitive by utilising our fully adaptable and scalable solution.'
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval